Cargando…
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer—a retrospective study
BACKGROUND: With the exception of very early-stage small cell lung cancer (SCLC), surgery is not typically recommended for this disease; however, incidental resection still occurs. After incidental resection, adjuvant salvage therapy is widely offered, but the evidence supporting its use is limited....
Autores principales: | Jin, Kai-Qi, Liu, Xiao-Gang, Guo, Yan-Hua, Wu, Chun-Xiao, Dai, Jie, Li, Jia-Qi, Minervini, Fabrizio, Antonoff, Mara B., Friedlaender, Alex, Addeo, Alfredo, Kocher, Gregor J., Grossi, Francesco, Zhu, Yu-Ming, Zhang, Peng, Jiang, Ge-Ning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554686/ https://www.ncbi.nlm.nih.gov/pubmed/36248336 http://dx.doi.org/10.21037/tlcr-22-616 |
Ejemplares similares
-
The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
por: Borgeaud, Maxime, et al.
Publicado: (2023) -
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
por: Parekh, Jay, et al.
Publicado: (2023) -
New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019) -
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020) -
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
por: Addeo, Alfredo, et al.
Publicado: (2020)